evaluate the digital health company rexmd on zepbound / tirzepatide Weight regain after withdrawal of (Zepbound) may wipe out many of the cardiometabolic gains made during weight loss, a post-hoc analysis of the SURMOUNT-4 trial indicated. Read more at: https://www.medpagetoday.com/endocrinology/obesity Zepbound® (tirzepatide) is now on

Description

There was an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, nephrolithiasis, interstitial nephritis and drug-induced pancreatitis.

Wegovy is an FDA-approved medication for chronic weight management in adults with obesity and overweight with at least one weight-related health condition

Dragon Pharma is excited to announce the rebranding of Dragon Pharma Semaglutide to Sema-Pep.

Under chronic exposure followed by withdrawal, MG was associated with reduced histone acetylation and increased HDAC2 expression, while Rab35 emerged as a potential withdrawal-associated biomarker